羅欣藥業(002793.SZ):已與全體業績承諾方就業績補償事宜達成一致意見
格隆匯8月20日丨羅欣藥業(002793.SZ)公佈,因重大資產重組標的山東羅欣藥業集團股份有限公司(“山東羅欣”)未完成2020年度、2021年度業績承諾,業績承諾方需對公司進行業績補償。
根據重大資產重組相關《盈利預測補償協議》及《盈利預測補償協議之補充協議》的約定,業績承諾方2020年度和2021年度應履行業績補償金額合計2,291,131,273.12元,摺合應補償股份合計371,334,114股。
截至公吿披露之日,公司已與全體業績承諾方就業績補償事宜達成一致意見。公司將盡快審議定向回購業績補償股份減少註冊資本的相關議案,履行減少註冊資本相關程序,並辦理業績補償股份回購註銷等手續,後續公司將根據進展情況及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.